Oppenheimer Asset Management Inc. Crinetics Pharmaceuticals, Inc. Transaction History
Oppenheimer Asset Management Inc.
- $7.94 Billion
- Q4 2024
A detailed history of Oppenheimer Asset Management Inc. transactions in Crinetics Pharmaceuticals, Inc. stock. As of the latest transaction made, Oppenheimer Asset Management Inc. holds 5,038 shares of CRNX stock, worth $203,535. This represents 0.0% of its overall portfolio holdings.
Number of Shares
5,038
Previous 4,216
19.5%
Holding current value
$203,535
Previous $215,000
19.53%
% of portfolio
0.0%
Previous 0.0%
Shares
3 transactions
Others Institutions Holding CRNX
# of Institutions
241Shares Held
80.1MCall Options Held
23.3KPut Options Held
44.3K-
Vanguard Group Inc Valley Forge, PA6.29MShares$254 Million0.01% of portfolio
-
Black Rock Inc. New York, NY6.23MShares$252 Million0.01% of portfolio
-
Driehaus Capital Management LLC Chicago, IL5.89MShares$238 Million2.95% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD4.94MShares$200 Million0.03% of portfolio
-
Wellington Management Group LLP Boston, MA4.46MShares$180 Million0.04% of portfolio
About Crinetics Pharmaceuticals, Inc.
- Ticker CRNX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 53,752,800
- Market Cap $2.17B
- Description
- Crinetics Pharmaceuticals, Inc., a clinical stage pharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for rare endocrine diseases and endocrine-related tumors. Its lead product candidate is Paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist that has completed phase III ...